Wiggin and Dana Counsels Olink Proteomics Holding AB in the sale of Olink Proteomics to Summa Equity
Wiggin and Dana LLP advised client Olink Proteomics Holding AB in the sale of Olink Proteomics to Summa Equity, a Swedish-based private equity firm. Olink Proteomics is a life science company that has developed a unique technology for human biomarker discovery. Olink’s purpose is to enable precision medicine through proteomics, thereby contributing to advancing healthcare worldwide.
Wiggin and Dana partners, Patti Melick and Mark Kaduboski, and counsel, James P. Greifzu, were lead counsel on the transaction. Other attorneys involved included Toby Bannon, Ben Diessel, Peter Gruen, and Brennan Gumerove.
J.P. Morgan Securities LLC served as Olink Proteomics’ financial advisor, and Wiggin and Dana co-counseled with the Swedish law firm, Lindahl.